Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
CAMBRIDGE, Mass., March 01, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016 at 8:40 a.m. ET.
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Jesse Baumgartner Stern Investor Relations, Inc. (212) 362-1200 [email protected]
